Vanda Pharmaceuticals Inc. (VNDA) › RevenueVanda Pharmaceuticals Inc. (VNDA) — RevenueAnnual figures by period end, from SEC filings.2011-12-31: $31.27M2012-12-31: $32.73M2013-12-31: $33.88M2014-12-31: $50.16M2015-12-31: $109.92M2016-12-31: $146.02M2017-12-31: $165.08M2018-12-31: $193.12M2019-12-31: $227.19M2020-12-31: $248.17M2021-12-31: $268.68M2022-12-31: $254.38M2023-12-31: $192.64M2024-12-31: $198.77M2025-12-31: $216.10M$216.10M2011-12-31Revenue (USD)2025-12-31Period endedRevenueChange YoYSource filing2025-12-31$216.10M+8.7%2026-02-12From 2025-01-012024-12-31$198.77M+3.2%2026-02-12From 2024-01-012023-12-31$192.64M-24.3%2026-02-12From 2023-01-012022-12-31$254.38M-5.3%2025-02-14From 2022-01-012021-12-31$268.68M+8.3%2024-02-08From 2021-01-012020-12-31$248.17M+9.2%2023-02-09From 2020-01-012019-12-31$227.19M+17.6%2022-02-24From 2019-01-012018-12-31$193.12M+17.0%2021-02-11From 2018-01-012017-12-31$165.08M+13.1%2020-02-26From 2017-01-012016-12-31$146.02M+32.8%2019-02-19From 2016-01-012015-12-31$109.92M+119.2%2018-02-15From 2015-01-012014-12-31$50.16M+48.0%2017-02-17From 2014-01-012013-12-31$33.88M+3.5%2016-02-12From 2013-01-012012-12-31$32.73M+4.7%2015-03-13From 2012-01-012011-12-31$31.27M—2014-02-25From 2011-01-01Other metrics: Cost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)